高级检索
当前位置: 首页 > 详情页

YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Inst Liver & Gastrointestinal Dis,Wuhan 430030,Peoples R China [2]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Hubei Key Lab Hepatopancreatobiliary Dis,Wuhan 430030,Peoples R China
出处:
ISSN:

关键词: Liver cancer YTHDF1 m(6)A PI3K AKT mTOR EMT

摘要:
Background N-6-methyladenosine (m(6)A) modification, as the most abundant RNA modification, widely participates in the physiological process and is involved in multiple disease progression, especially cancer. YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) is a pivotal m(6)A "reader" protein, which has been reported in multiple cancers. However, the role and molecular mechanism of YTHDF1 in HCC are still not fully elucidated. Methods Based on various bioinformatics databases, q-RT PCR, western blot, and a tissue microarray containing 90 HCC samples, we examined the expression of YTHDF1 in HCC. Then, we applied the loss-of-function experiments to explore the role of YTHDF1 in HCC by in vitro and in vivo assays. Finally, we performed the gene set enrichment analysis (GSEA) to predict the potential signaling pathway of YTHDF1 involved in HCC and further verified this prediction. Results YTHDF1 was overexpressed in HCC and associated with HCC grade. Depletion of YTHDF1 markedly impaired the proliferation, migration, invasion, and cell cycle process of HCC cells. Mechanistically, YTHDF1 promoted the growth of HCC cells via activating the PI3K/AKT/mTOR signaling pathway. Moreover, we also demonstrated that the epithelial-mesenchymal transition (EMT) mediated the promoting effect of YTHDF1 on the migration and invasion of HCC cells. Conclusions YTHDF1 contributes to the progression of HCC by activating PI3K/AKT/mTOR signaling pathway and inducing EMT.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 3 区 医学
小类 | 3 区 血液学 3 区 肿瘤学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 血液学 2 区 肿瘤学
JCR分区:
出版当年[2019]版:
Q2 HEMATOLOGY Q2 ONCOLOGY
最新[2023]版:
Q1 HEMATOLOGY Q1 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Inst Liver & Gastrointestinal Dis,Wuhan 430030,Peoples R China [2]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Hubei Key Lab Hepatopancreatobiliary Dis,Wuhan 430030,Peoples R China
通讯作者:
通讯机构: [1]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Inst Liver & Gastrointestinal Dis,Wuhan 430030,Peoples R China [2]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Hubei Key Lab Hepatopancreatobiliary Dis,Wuhan 430030,Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:426 今日访问量:0 总访问量:408 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)